LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.

Authors

Barbara Burtness

Fox Chase Cancer Center, Philadelphia, PA

Barbara Burtness , Jean Bourhis , Jan Baptist Vermorken , Luyan Dai , Charlotte Lind , Eva Ehrnrooth , Ezra E. W. Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

First Author: Yuming Zhu

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.

First Author: C. Liberatoscioli

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.

First Author: Jean-Pascal H. Machiels

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.

First Author: Melissa Lynne Johnson